Participate in the Growth Hormone Disorder (GHD) Webinar
Stay up to date to provide timely diagnosis and treatment of GHD
Growth hormone deficiency (GHD) affects more than 50,000 adults in the United States, with 6,000 new cases reported each year. These cases include the continuation of child-onset GHD into adulthood and those caused by damage to the hypothalamic-pituitary axis. While adult onset GHD has been predominantly associated with oncologic causes and their treatment, an increasing number of adult GHD cases have been reported following traumatic brain injury (TBI). TBI represents a leading cause of death and disability in the United States (2) and greatly expands the number of patients at risk for GHD following motor vehicle accidents, falls, sports-related head traumas, combative sports, and veterans returning from combat service.
Upon completion of this activity, participants should be better able to:
- Explain the signs and symptoms of growth hormone deficiency
- Evaluate evidence-based testing strategies for GHD
- Design individualized treatment strategies
- The intended audience for this activity consists of endocrinologists, primary care providers, neurologists, and psychiatrists.
- This activity consists of one session which should take approximately 1 hour to complete.
- There are no fees to participate in this activity.
- Kevin CJ Yuen, MD, FRCP (UK), FACE
- Andrew R. Hoffman, MD
- Beverly M.K. Biller, MD, FACP
To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post test.